Incidence of COVID-19-Associated Hospitalization by Vaccination Status in Children and Adolescents During Omicron-Dominant Period in Japan: The VENUS Study
Open Access
Abstract
Background/Objectives: Evidence regarding the impact of COVID-19 vaccination on children and adolescents remains limited, particularly in Japan. Thus, this study aimed to estimate incidence rates of COVID-19-associated hospitalization by vaccination status and evaluate the association between COVID-19 vaccination and COVID-19-associated hospitalization among individuals aged 6 months to <18 years in Japan. Methods: We conducted a retrospective, population-based cohort study using linked health insurance claims data and municipal COVID-19 vaccination registry records from nine Japanese municipalities between 1 January 2022, and 31 March 2023, when the Omicron variant was dominant nationwide. Incidence rates of COVID-19-associated hospitalization were estimated among unvaccinated individuals and those who had received one dose (partially vaccinated) or at least two doses of an ancestral monovalent COVID-19 vaccine (fully vaccinated). Incidence rate ratios (IRRs) were calculated, adjusting for age group, sex, presence of underlying medical conditions, municipality, and calendar month. Results: Among 163,305 individuals, 93 COVID-19-associated hospitalizations were identified. Crude incidence rates were 4.5 (95% confidence interval [CI]: 3.6–5.6), 3.2 (95% CI: 0.1–18.0), and 2.3 (95% CI: 1.1–4.2) per 100,000 person-months in unvaccinated, partially, and fully vaccinated groups, respectively. The adjusted IRR for the fully vaccinated group was 0.429 (95% CI: 0.198–0.930). Among hospitalized patients, 30.1% had underlying medical conditions, and only 4.3% required oxygen administration during hospitalization. Conclusions: Receiving at least two doses of COVID-19 vaccine was associated with a lower incidence rate of COVID-19-associated hospitalization among children and adolescents during the Omicron-dominant period in Japan. Expanding vaccine uptake among eligible pediatric populations may help reduce the burden of severe disease.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP24fk0108709)
This publication has 34 references indexed in Scilit:
- COVID-19 vaccine effectiveness and duration of protection among children and adolescents: A retrospective cohort study in 11 large cities in JapanVaccine, 2025
- Pediatric COVID-19 severity by SARS-CoV-2 lineage and vaccine status in Canada: an IMPACT studyPediatric Research, 2025
- COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: A Canadian immunization research network (CIRN) studyVaccine, 2024
- Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS studyVaccine, 2023
- Impact of changing case definitions for coronavirus disease 2019 (COVID-19) hospitalization on pandemic metricsInfection Control & Hospital Epidemiology, 2023
- Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort studyThe Lancet Infectious Diseases, 2022
- Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022The Lancet, 2022
- Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational studyThe Lancet Child & Adolescent Health, 2022
- Underlying Medical Conditions Associated With Severe COVID-19 Illness Among ChildrenJAMA Network Open, 2021
- Older Adults Hospitalized with Covid-19: Clinical Characteristics and Early Outcomes from a Single Center in Istanbul, TurkeyThe Journal of nutrition, health and aging, 2020